News >

Immunotherapy Research Continues to Improve Patient Selection in NSCLC

Ellie Leick
Published: Tuesday, Feb 04, 2020

Roy Herbst, MD, PhD, chief of Medical Oncology, professor of Medicine, Yale Cancer Center, Smilow Cancer Hospital

Roy Herbst, MD, PhD

Nivolumab (Opdivo) plus ipilimumab (Yervoy) in the frontline setting for patients with advanced non–small cell lung cancer (NSCLC) led to an improvement in overall survival (OS) over chemotherapy, regardless of PD-L1 expression, according to data from the phase III CheckMate-227 trial, explained Roy S. Herbst, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication